Purpose: Recent evidence suggests that cancer stem cells (CSC) are responsible for key elements of colon cancer progression and recurrence. Germline variants in CSC genes may result in altered gene function and/or activity, thereby causing interindividual differences in a patient's tumor recurrence capacity and chemoresistance. We investigated germline polymorphisms in a comprehensive panel of CSC genes to predict time to tumor recurrence (TTR) in patients with stage III and high-risk stage II colon cancer.
Introduction
Adjuvant treatment is recommended for patients with stage III and high-risk stage II colon cancer. The risk of tumor recurrence can be significantly reduced by treating these patients with 5-fluorouracil (5-FU)-based chemotherapy. The addition of oxaliplatin to 5-FU-based chemotherapy is now a standard adjuvant treatment for colon cancer, with a higher 5-year disease-free survival (DFS) rate, compared with 5-FU-based treatment alone (73.3% vs.
67.4%; ref. 1).
However, a considerable number of patients will relapse despite adjuvant treatment (2) .
Tumor recurrence after curative surgery remains a major obstacle for improving overall cancer survival, which may be in part due to the existence of cancer stem cells (CSC). Growing evidence suggests that human cancers are stem cell diseases and only a small subpopulation of cancer cells, endowed with stem cell-like features, might be responsible for tumor initiation, progression and chemoresistance (3) . Cancer cells with the properties of stem cells possess the ability to self-renew, to undergo multilineage differentiation, and to survive an adverse tissue microenvironment.
Putative CSC populations have been identified in colon cancer on the basis of the expression of specific markers and their functional properties; however, phenotypic characterization of colon CSCs is still a matter of debate and ongoing research studies (4) . Ideally, definitive markers should be gene products that are coupled to the function of the stem cell. CSC markers in colon cancer include CD133, CD44, and CD166 (5) . More recently, EpCAM, CD26, Msi-1, CD29, CD24, LGR5, and ALDH1A1 have been added to the list of putative stem cell markers for colon cancer (6, 7) . These colon CSC markers are representative of a range of pathways including the Wnt-target genes, cell adhesion molecules, RNA-binding proteins, and detoxifying enzymes, and play distinct roles in a variety of processes including cell differentiation, proliferation, migration, apoptosis, adhesion, lymphocyte homing, angiogenesis, and cellular response to chemotherapy (8) . Current therapies target populations of rapidly growing and differentiated tumor cells, but have been shown to lack activity against CSCs (4). CSCs therefore may have an important role in tumor recurrence despite adjuvant chemotherapy. Thus far, preclinical studies in colon cancer have identified that CSCs are capable of initiating tumor development, however, little is known about the role of CSCs in colon cancer tumor recurrence.
There is substantial germline genetic variability within the genes used as markers to identify CSCs, including multiple single nucleotide polymorphisms (SNP) . These common DNA-sequence variations may alter the gene function and/or activity including transcription, translation or splicing, thereby causing interindividual differences in relation to tumor recurrence capacity and chemoresistance (9) . We recently tested the impact of common gene variants in the cell surface glycoprotein, CD44, a gastric and colon CSC marker, on clinical outcome of patients with localized gastric adenocarcinoma and found that the minor allele of CD44 rs187116 was significantly associated with decreased time to tumor recurrence (TTR) and overall survival (OS), identifying a "high-risk" patient population based on a germline genetic variant (10) .
In this study, we investigated 25 germline polymorphisms in a comprehensive panel of genes that have been previously associated with colon CSC to predict tumor recurrence in patients with stage III and high-risk stage II colon cancer. The analyzed CSC genes included CD44, Prominin-1 (CD133), dipeptidyl peptidase-4 (DPP4/ CD26), epithelial cell adhesion molecule (EpCAM), activated leukocyte cell adhesion molecule (ALCAM/CD166), musashi homolog-1 (MSI-1), integrin beta-1 (ITGB1/ CD29), CD24, leucine-rich repeat containing G proteincoupled receptor-5 (LGR5), and aldehyde dehydrogenase-1 family member A1 (ALDH1A1). To the best of our knowledge, this is the first study investigating common germline genetic variants in a comprehensive panel of colon CSC genes to predict tumor recurrence. This study was conducted adhering to the reporting recommendations for tumor marker prognostic studies (11) (12) (13) .
Patients and Methods

Eligible patients
A total of 234 patients with stage III and high-risk stage II colon cancer were included in this study. High-risk stage II colon cancer patients were defined if they presented with at least one of the following features: lymph node sampling less than 12; poorly differentiated tumor; vascular, lymphatic or perineural invasion; tumor presentation with obstruction or perforation and pT4. All patients were treated with 5-FU-based adjuvant chemotherapy at the Norris Comprehensive Cancer Center/University of Southern California (NCCC/USC) or the Los Angeles County/USC-Medical Center (LAC/USCMC) from 1987 to 2007. All patients were included in the colon cancer surveillance program of NCCC/USC or LAC/USCMC, providing history and physical examination and CEA determination every 3 months for 3 years and every 6 months at years 4 and 5 after surgery, colonoscopy at year 1 and thereafter every 3 to 5 years and CT scans of chest and abdomen every 6 months for the first 3 years. Patient data were collected retrospectively through chart review. Whole blood was collected at the time of diagnosis and stored at À80
C. Blood samples from 216 patients were available for current genetic analyses. The study was approved by the Institutional Review Boards at USC and all study participants signed informed consent for the analysis of molecular correlates.
Candidate polymorphisms
Common and putatively functional polymorphisms within genes that have been previously associated with colon CSC were selected using public literature resources and databases including: NCBI-PubMed, dbSNP, Ensembl, GeneCards, and the Pharmacogenomics-Knowledge-Base. Stringent and predefined selection criteria used were: (a) minor allele frequency 10% or more in Caucasians; (b) polymorphism that could alter the function of the gene in a biologically relevant manner [either published data or predicted function using Functional-Single-Nucleotide-Polymorphism (F-SNP) database, http://compbio.cs.queensu. ca/F-SNP (14, 15) ]; and (c) published clinical associations (e.g., cancer risk/outcome or chemoresistance; Table 1 ).
Genotyping
Genomic DNA was extracted from peripheral blood using the QIAmp-kit (Qiagen). The majority of the samples were tested using PCR-based restriction fragment length
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polymorphism (PCR-RFLP) analysis. Forward and reverse primers were used for PCR amplification, PCR products were digested by restriction enzymes (New England Biolabs), and alleles were separated on 4% NuSieve ethidium bromide stained agarose gel. If no matching restriction enzyme could be found, samples were analyzed by direct DNA-sequencing. For quality control purposes, a total of 5% PCR-RFLP analyzed samples were reanalyzed by direct DNA-sequencing. The investigator analyzing the germline polymorphisms was blinded to the clinical dataset.
Statistical analysis
The endpoint of the study was TTR. TTR was calculated from the date of diagnosis of colon cancer to the date of the first observation of tumor recurrence. TTR was censored at the time of death or at the last follow-up if the patient remained tumor recurrence-free at that time. With 216 patients, there was an 80% power to detect a minimum HR of 1.8 across the range of minor allele frequencies (0.2-0.5) for TTR using a dominant model. For the recessive model, the minimum HR was 3.1 when the allele frequency was 0.2 and approaches 1.8 when the allele frequency was 0.5. Allelic distribution of the polymorphisms by ethnicity was tested for deviation from Hardy-Weinberg equilibrium using x 2 test. The distribution of polymorphisms across baseline demographic, clinical, and pathologic characteristics was examined using Fisher's exact test. The true mode of inheritance of all polymorphisms tested is not established yet and we assumed a codominant, additive, dominant or recessive genetic model where appropriate. The association of polymorphisms with TTR was analyzed using Kaplan-Meier curves and log-rank test. In the multivariate Cox-regression analysis, the model was adjusted for stage and type of adjuvant chemotherapy, and stratified by ethnicity. Interactions between polymorphisms and stage and gender on TTR were tested by comparing likelihood ratio statistics between the baseline and nested Cox proportional hazards models that include the multiplicative product term. P values for all polymorphisms were adjusted for multiple testing using a modified test of Conneely and Boehnke that was applied for the correlated tests due to linkage disequilibrium and the different modes of inheritance considered (16) . Recursive partitioning (RP), including cross validation, was used to explore and identify polymorphism profiles associated with TTR using the rPart-function in S-plus (17, 18) . Case-wise deletion for missing polymorphisms was used in univariate and multivariate analyses. In the RP-analysis, all patients with at least one polymorphism result available were included. All analyses were done using SAS 9.2 (SAS Institute Inc.).
Results
The baseline characteristics of the 234 patients included in this analysis are summarized in Table 2 . The median age at time of diagnosis was 59 years (range 22-87), with a median follow-up time of 4.4 years (range 0.4-16.8). Ninety (38.5%) patients showed tumor recurrence, with a stage III and high-risk stage II dependent probability of 3-year recurrence of 0.45 AE 0.047 and 0.21 AE 0.043, respectively.
Median OS has not been reached yet. The genotyping quality control by direct DNA-sequencing provided a genotype concordance of 99% or more. Genotyping was successful in at least 90% of cases for each polymorphism analyzed, with the exception of CD44 rs8193 (88.4%). In failed cases, genotyping was not successful because of limited quantity and/or quality of extracted genomic DNA. The allelic frequencies for all polymorphisms were within the probability limits of Hardy-Weinberg equilibrium, with the exception of EpCAM rs17036526 (data not shown).
There were no significant associations between the polymorphisms and baseline demographic, clinical or pathologic characteristics (data not shown). In the univariate analysis, the minor alleles of CD44 rs8193 C>T, ALCAM rs1157 G>A and LGR5 rs17109924 T>C were significantly associated with an increased TTR. Patients carrying at least one T allele in CD44 rs8193 showed a median TTR of 9. In the multivariate analysis stratified by ethnicity, the minor alleles of CD44 rs8193 C>T, ALCAM rs1157 G>A and LGR5 rs17109924 T>C remained significantly associated with increased TTR (Table 3) . There was no significant interaction between the polymorphisms and tumor stage or gender on TTR (P values for interactions less than 0.05). In multiple testing including all polymorphisms analyzed, none of them remained significantly associated with TTR (adjusted-P for CD44 rs8193 ¼ 0.142; adjusted-P for ALCAM rs1157 ¼ 0.199; adjusted-P for LGR5 rs17109924 ¼ 0.394) When RP was used to construct a decision tree as a predictive model to classify patients based on the gene variants, high-and low-risk patient subgroups were identified. In the resultant tree, the most important factor that determined the TTR in these patients was LGR5 rs17109924. Patients carrying the combination of LGR5 rs17109924 wild type and at least one CD44 rs8193 wildtype allele and the mutant variant of ALDH1A1 rs1342024 showed a TTR of 1.7 years (node 5) compared with 10.7 years in patients with the minor allele of LGR5 rs17109924 (node 1) or the combination of LGR5 rs17109924 wildtype and CD44 rs8193 mutant variant (node 2; HR, 6.71, 95% CI: 2.71-16.63, P < 0.001; Fig. 2 ).
To evaluate whether the high-risk patients identified from our gene variant profile benefit from combination chemotherapy (n ¼ 47) compared with 5-FU alone (n ¼ 66), the cases from node 4 and 5 of the decision tree were combined for further analysis. According to the treatment regimen, no 
Discussion
In this study, we investigated germline polymorphisms in a comprehensive panel of genes that have been previously associated with colon CSC to predict tumor recurrence in patients with stage III and high-risk stage II colon cancer. The results indicate that common CSC gene variants in CD44, ALCAM, LGR5, and ALDH1A1 may be valuable to separate high-risk from low-risk colon cancer patients.
The detailed molecular mechanisms involved in how the CD44 rs8193, ALCAM rs1157, LGR5 rs17109924, and ALDH1A1 rs1342024 polymorphisms exert effects on colon cancer are unclear. Nonsynonymous polymorphisms lead to amino acid changes and thus may affect the protein function (19) (20) . We used the F-SNP database to predict the functional effects of the analyzed polymorphisms. F-SNP gathers computationally predicted functional information about polymorphisms, particularly aiming to facilitate identification of disease-related polymorphisms in association studies (14, 15) . When used for this study set of polymorphisms, F-SNP predicted changes in transcription factor binding to the 3 0 UTR located CD44 rs8193 and ALCAM rs1157, and changes in splicing regulation and protein coding for the nonsynonymous LGR5 rs17109924, thus supporting the effects seen in our study. No prediction could be provided for the upstream located ALDH1A1 rs1342024 by the software.
CD44-signaling is crucial in cancer cell proliferation, motility, and migration. As a Wnt-target gene, CD44 promotes cell proliferation via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. CD44 positive colon cancer cells have been reported to possess the capacity for selfrenewal, longevity, and multipotency (21) . ALCAM belongs to the immunoglobulin superfamily of cell adhesion molecules involved in cell-cell interactions. ALCAM may regulate through cytoskeletal anchoring and the integrity of the extracellular immunoglobulin-like domains complex cellular properties in regard to cell adhesion, migration, and growth (22) . Isolation of ALCAM/CD44 double-positive cells from human colon cancer cells can recapitulate tumorigenesis when xenografted at low numbers into immunedeficient mice which represents a hallmark of CSCs (5). Despite the potentially high clinical relevance of these CSC markers, little is known about their prognostic significance in colon cancer and contradictory findings have been reported. In a recent study based on 110 colorectal cancer (CRC) patients, membranous expression of CD44 and ALCAM did not predict survival in single-marker analyses, but gained significance when combined (23) . In contrast, Weichert and colleagues found a correlation between membranous ALCAM expression and decreased survival in 111 CRC patients (24) . Interestingly, loss, rather than overexpression, of membranous CD44 and ALCAM was correlated to outcome in an analysis including 101 CRC patients. The authors suggested that their results are in large part dependent on the cell adhesion function of CD44 and ALCAM with loss of cell adhesion representing a These conflicting results raised the question whether germline genetic variants putatively changing the gene's function rather than membranous evaluation of these proteins may predict colon cancer patient's outcome. We recently showed that the minor allele of CD44 rs187116 predicts decreased TTR and OS in patients with localized gastric adenocarcinoma (10) . More recently, Zhou and colleagues analyzed 2 polymorphisms in ALCAM Additional experiments showed that the T allele was associated with a higher transcriptional activity of the ALCAM gene (26) . Both polymorphisms, CD44 rs187116 and ALCAM rs6437585, did not show any clinical associations in this study. However, these SNPs have been analyzed in other tumor entities and/or setting (risk assessment) and therefore might not exert their effects in colon cancer and tumor recurrence assessment. Because CD44 rs8193 and ALCAM rs1157 may change transcriptional factor binding to the polymorphic region of the gene as predicted by F-SNP, the findings in this study that these gene variants affect TTR in colon cancer are biologically plausible. Taking into account the clinical association found in our study and the predicted function by F-SNP, we hypothesize that the wild-type genotype of CD44 rs8193 is associated with a higher transcriptional activity of the CD44 gene leading to a lower TTR in our study cohort. For ALCAM expression and clinical outcome in colon cancer conflicting results can be found in the literature, therefore we cannot assess the molecular mechanisms involved in how the ALCAM rs1157 polymorphism exerts its effects on colon cancer and studies elucidating the exact biological function of the ALCAM rs1157 polymorphism should be under future consideration. Interestingly, the tree analysis provided LGR5 rs17109924 as the first split indicating the most important factor determining TTR in this patient cohort.
LGR5 is a member of the G-protein-coupled receptor family comprising proteins with 7 transmembrane domains. G-protein-coupled receptors function as receptors for various classes of ligands, including peptide hormones and chemokines; however, the ligand for and function of LGR5-related signaling remains unclear.
LGR5, a Wnt-target gene, has been reported to be a marker for colon CSC, thus playing a putative role in the biological function of stem cells. In a recent study, high membranous LGR5 expression was shown to predict lower DFS in CRC patients (27) (28) (29) . LGR5 rs17109924 represents a nonsynonymous SNP and was predicted to affect splicing regulation and protein coding by F-SNP. In addition, LGR5 rs17109924 predicted TTR in both the univariate and multivariate analysis and was incorporated in the tree analysis, strongly indicating that this SNP has functional significance. Taking into account the clinical association found in our study and the predicted function by F-SNP, we hypothesize that the LGR5 rs17109924 wild-type genotype is associated with a higher protein expression of the LGR5 gene leading to a lower TTR in our study cohort.
A combination of gene variants in the tree analysis defined a high-risk subgroup with significantly lower TTR by incorporating ALDH1A1 rs1342024 when compared with single marker analysis. ALDH1 is a detoxifying enzyme that oxidizes intracellular aldehydes. This detoxification capacity may protect stem cells against oxidative insult (30, 31) . Taking into account the clinical association found in our study, we hypothesize that the mutant variant of ALDH1A1 rs1342024 is associated with a higher detoxification capacity of ALDH1 leading to a lower TTR in our study cohort when incorporated in the decision tree algorithm. In a recent study, membranous ALDH1 expression did not predict survival in CRC patients (25) . Although the mechanism of ALDH1A1 rs1342024 remains unclear, our data suggest that a multigenic approach, which assesses the combined effects of gene variants, may detect synergistic interactions between individual SNPs thus enhancing the predictive power of the model. This study further used multiple testing due to the large number of independent genetic variants evaluated. Application of a modified test of Conneely and Boehnke resulted in a nonsignificant adjusted P value for CD44 rs8193, ALCAM rs1157, and LGR5 rs17109924. Therefore, these data warrant further validation in a larger cohort. Nevertheless, the biological plausibility and our translational findings hold promise for further investigations in independent study populations. In a subanalysis combining high-risk patients based on our gene variant profile, no benefit for the addition of oxaliplatin or irinotecan to 5-FU-based chemotherapy could be shown. Because all patients included in this study represent stage III and high-risk stage II colon cancer treated with adjuvant therapy, it was not possible to correlate the genotypes with clinical outcome in an untreated control group. As a consequence, it could not be determined whether the high-risk patients, based on the gene variant profile, did not benefit from combination chemotherapy or from chemotherapy at all.
This study provides the first evidence that germline polymorphisms in CSC genes predict early tumor recurrence in patients with colon cancer. This may help to select subgroups of patients who may benefit from more aggressive treatment strategies or newly developed stem cell targeting drugs. Future biomarker-embedded translational trials are warranted to validate these findings.
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